Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for...
Read More Details
Finally We wish PressBee provided you with enough information of ( WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA )
Also on site :
- Brynn Whitfield Announces Exit From 'RHONY' After Two Seasons
- Pop Princess Covers Classic ‘70s Rock Hit: ‘This Is So Good’
- Born on One of These 4 Dates? You're a Wise, Old Soul